GH Stock — Guardant Health, Inc.

Up next

Next earnings call

Oct 26, 2026 Est · unconfirmed · in 3 wks

Latest filing: 10-Q

filed Jul 30, 2026

Q2 2026 earnings call transcript

call held Jul 30, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

—

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

—

Year over year · more shares

Price change (1Y)

+189.3%

Trailing year

Short interest

8.2%

Latest settlement · 6.6 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Jul 30, 2026

Q2 FY26

TL;DR. Guardant Health reported Q2 2026 revenue of $335 million, up 44% year-over-year, driven by 63% oncology volume growth and over 250% screening revenue growth, and raised full-year 2026 revenue guidance to $1.34–$1.36 billion (36–38% growth), with guidance also raised for oncology volume to ~50% and screening revenue to $218–$230 million.

Bullish

+ Raised full-year 2026 oncology volume growth guidance to ~50% from prior ~35%, with oncology revenue growth now expected at ~30%.
+ Raised screening revenue guidance to $218–$230 million and Shield volume to 270,000–285,000 tests from prior 230,000–245,000.
+ Received UnitedHealth Group coverage for Shield, the first major commercial insurer, covering approximately 70 million lives (~60% of the market).
+ Shield included in American Cancer Society colorectal cancer screening guidelines, making Shield the only FDA-approved blood test in both ACS and NCCN guidelines.
+ Q2 revenue grew 44% year-over-year to $335 million, with oncology volume up 63% and Shield volume up from ~16,000 to ~66,000 tests.

Bearish

− Raised full-year 2026 non-GAAP operating expense guidance to $1.08–$1.10 billion (20–22% growth), up from prior $1.05–$1.07 billion.
− Raised full-year free cash flow burn guidance to $195–$205 million from prior $185–$195 million, citing accelerated Shield lab capacity investment.
− Free cash flow burn in Q2 widened to $69.5 million from $65.9 million year-over-year due to elevated capex on screening lab automation and infrastructure.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +43%

above

Price vs 50-day avg +8%

above

RSI (14) 58

neutral

MACD trend Negative

52-week position 96%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +10%

trailing

6-month return +116%

trailing

YTD return +74%

this year

Relative strength +104%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $165 › 200d $124 — 50d above 200d

Institutional flow Accumulating

3 of 604 funds reported for Sep 30 · net +194 sh shares · +1 new

Insider flow Distributing

Net -$30.5M over 90 days · 100% sells

Short interest Falling

8.21% of float · ▼ -0.3% MoM · 6.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

604 holders — near 3-yr high, broad support

Squeeze score 69

elevated · 0–100

Fundamentals

Weak

Revenue growth +33%

Y/Y

EPS growth +7%

Y/Y

Free cash flow $-233.1M

Balance sheet $1.1B

net debt

Quant / Vol

risk profile

Very High

Volatility 58%

annualized · 1-yr

Max drawdown −33%

past year

ATR 4.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 2 of last 2

Latest guidance · from the 8-K filed Jul 30, 2026

full year 2026

Full year 2026 revenue Initiated $1.34B – $1.36B

prior FY $982.02M midpoint +37.5% Y/Y

Non-GAAP gross margin Non-GAAP Initiated 64% – 65%

2026

Screening revenue $218M – $230M

Oncology volume growth 50%

Total non-GAAP operating expenses Non-GAAP $1.08B – $1.1B

full-year 2026

Free cash flow burn Initiated $195M – $205M

Guided vs delivered · last 2 settled

Full year 2023 revenue full year 2023

guided $553M – $556M

guided $553M – $556M $563.95M Beat +1.7%

Revenue full-year 2021

guided $360M – $370M

guided $360M – $370M $373.65M Beat +2.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+43% Bullish

Price vs 50-day avg

+8% Bullish

RSI (14)

58 Neutral

MACD trend

Negative Bearish

52-week position

96% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $165 › 200d $124 — 50d above 200d

Institutional flow Accumulating

3 of 604 funds reported for Sep 30 · net +194 sh shares · +1 new

Insider flow Distributing

Net -$30.5M over 90 days · 100% sells

Short interest Falling

8.21% of float · ▼ -0.3% MoM · 6.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

604 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $61 Now $178 · 96% Range high $183

vs 200-day avg +43% vs 50-day avg +8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Diagnostics & Research — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
GH Guardant Health, Inc. this stock	$23.79B	+74.1%	+32.9%	—	8.2%
TMO Thermo Fisher Scientific Inc.	$249.58B	+13.0%	+14.5%	36.3	1.4%
DHR Danaher Corp /De/	$150.37B	-6.5%	+8.5%	37.9	1.2%
NTRA Natera, Inc.	$59.47B	+79.1%	-2.8%	—	3.3%
A Agilent Technologies, Inc.	$48.90B	+23.3%	+6.4%	34.2	1.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

605

% held: 101.2%
Reported: 3 of 604
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

631

View

Short & Settlement

Short Interest Falling

Shares short

11.0M

Days to cover: 6.6d
Change: -31.9K sh

View

Short Volume

Short vol %

49%

As of: Oct 2, 2026

Short Total

View

Fails to Deliver

FTD shares

128

Value: $20.8K
As of: Sep 10, 2026

View

Off-Exchange

Off-exchange %

49.5%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$30.5M

Buyers / Sellers: 0 / 8

Buyers Sellers

View

Congressional Trades Buy

Member

Sheldon Whitehouse

Amount: $1.0K–$15.0K
Traded: Nov 21, 2025

View

Financials

Revenue (FY)

$982.0M

Net income (FY): $-416.3M
EPS diluted: $-3.32

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 15, 2026
This year: 15

View

Proposed Sales

Value

$20.3K

Shares: 116
Filed: Sep 16, 2026

View

Earnings & Events

Webcasts

Last webcast

Sep 15, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
GH	+0.3%	+10.4%	+116.3%	-0.3%	+74.1%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	+0.5%	+10.9%	+104.1%	-1.2%	+61.2%

GH · Guardant Health, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance